Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Bone and Calcium Disorders
Is there any data on denosumab use beyond 10 years from the FREEDOM Extension trial, and what do we know about the risk of atypical femoral fracture and osteonecrosis of the jaw after 10 years?
Related Questions
Is the 6-month post-operative calcium level a good indicator of patients' risk of recurrence of primary hyperparathyroidism?
Under what circumstances would you consider a bone biopsy in the workup of renal osteodystrophy?
When stopping denosumab and transitioning to PO bisphosphonate, do you wait for 6 months after the last denosumab injection to start PO bisphosphonate?
Can a 60-year-old male have a bone density test showing a normal T-score but a low Z-score?
What patient factors are most important when considering who needs a broader workup for osteoporosis prior to starting therapy?
How do you approach vitamin D supplementation in patients with chronic kidney disease, given the findings that vitamin D2 supplementation may lead to decreased conversion of 25-hydroxyvitamin D3 to 1,25-dihydroxyvitamin D3?
In post-bariatric surgery patients presenting with secondary hyperparathyroidism, what is the optimal approach to assess calcium supplementation adequacy?
Do you temporarily hold diuretics when measuring 24-hour urine calcium levels in the evaluation of primary hyperparathyroidism?
Which osteoporosis medication is best at improving bone density and hence fracture risk in the wrist?
Would you start romosozumab in an active smoker?
